LOGIN
Rivaroxaban Versus Enoxaparin As Thromboprophylaxis In Degenerative Spine Surgery
July 2025
Rivaroxaban Versus Enoxaparin As Thromboprophylaxis In Degenerative Spine Surgery
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study.
Eur Spine J . 2025 May;34(5):1926-1933.Synopsis
Two hundred twenty patients undergoing degenerative spine surgery were randomized to receive either enoxaparin 40 mg subcutaneously once daily (n=110) or rivaroxaban 10 mg orally once daily (n=110). The primary outcome was the incidence of venous thromboembolism (VTE) (DVT and PE). Secondary outcomes included reoperation rate, length of hospital stay, surgical site infection, CSF leakage, and oth...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.